IL6 and COVID-19: The anti-inflammatory effects of PCSK9 inhibitors have been widely reported, especially for the interleukin-6 (IL-6)-mediated inflammatory signaling pathway (99–101), which is a driving factor for more severe inflammation in COVID-19 (102).